Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Radiotherapy 53 Prednisone 53 Docetaxel 51 Leuprolide 48 Goserelin 47 bicalutamide 45 enzalutamide 28 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27 Androgen Antagonists 26 Flutamide 24 Triptorelin Pamoate 22 apalutamide 18 Gonadotropin-Releasing Hormone 17 Abiraterone Acetate 17 Radiation 15 abiraterone 14 Zoledronic Acid 14 Magnetic Resonance Spectroscopy 13 gallium 68 PSMA-11 12 Prednisolone 11 luprolide acetate gel depot 10 darolutamide 9 cabazitaxel 8 Standard of Care 8 Specimen Handling 8 Radiosurgery 8 Estramustine 8 Dexamethasone 8 Buserelin 8 Radiotherapy, Intensity-Modulated 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡